Apply now through December 13 for HF-Cert™! Open to members of the HF team in many disciplines!
2023 | HFSA

JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

Industry News In The News

Oak Ridge, TN – July 12, 2023 — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. 

The study, titled “Discordant Pressure-Volume Trends During CardioMEMS Monitoring,” evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor’s blood volume analysis (BVA) diagnostic. Veraprapas Kittipibul M.D., lead investigator of the study reported statistically insignificant correlation between the two diagnostics and concluded, “Less than half of patients had concordant pressure-volume changes during CardioMEMS monitoring. Universal volume-directed interventions (i.e., diuretics) in HF patients with high pressures might not be appropriate and should be discouraged.”